{"id":3071,"date":"2026-09-03T00:00:00","date_gmt":"2026-09-03T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3071"},"modified":"2026-09-12T10:41:05","modified_gmt":"2026-09-12T14:41:05","slug":"china-approves-rilzabrutinib-for-persistent-or-chronic-itp","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3071","title":{"rendered":"China Approves Rilzabrutinib for Persistent or Chronic ITP"},"content":{"rendered":"

Evidence<\/strong> Regulatory disclosure · Discovery<\/strong> September 11, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Positive<\/p>\n

\"China<\/p>\n

Summary<\/h4>\n

China’s National Medical Products Administration approved Genzyme Corporation’s rilzabrutinib tablets, branded Sailizhi in China, for adults with persistent or chronic primary immune thrombocytopenia who respond inadequately to or cannot tolerate corticosteroids, immunoglobulin or other prior therapy. The September 3 disclosure was missed by earlier Insilens passes and is reported as a regulatory catch-up. Rilzabrutinib is an oral, reversible covalent BTK inhibitor already approved in the United States and other markets. The approval adds a mechanistically differentiated option in a chronic rare blood disorder, while uptake will depend on labeling details, reimbursement, treatment sequencing and real-world safety.<\/p>\n

What Happened<\/h4>\n

The NMPA described rilzabrutinib as a Class 1 innovative drug and identified Genzyme Corporation, a Sanofi company, as the applicant. The approved population is adults with persistent or chronic primary ITP after inadequate response or intolerance to prior corticosteroid, immunoglobulin or other therapy. The global Phase 3 LUNA 3 trial randomized 202 previously treated adults to rilzabrutinib 400 mg twice daily or placebo. The peer-reviewed study reported a statistically significant durable platelet-response advantage, reduced rescue-therapy use and bleeding, and improved fatigue. The China approval notice did not state whether local bridging analyses, subgroup data or postmarketing commitments modified the benefit-risk assessment.<\/p>\n

Deep Analysis<\/h4>\n

A meaningful mechanism and market expansion:<\/strong> BTK inhibition can modulate B-cell activation, autoantibody signaling, Fc-receptor-driven platelet clearance and inflammatory pathways without being designed primarily to stimulate platelet production. Approval in China broadens access and validates a non-TPO-receptor strategy in a large market. Supporting evidence includes randomized Phase 3 outcomes and prior US approval. Constraints include twice-daily dosing, drug-interaction management and uncertain positioning versus thrombopoietin-receptor agonists, fostamatinib, splenectomy and other immunomodulators.<\/p>\n

Clinical differentiation may narrow in routine practice:<\/strong> The trial’s durable-response endpoint applied a demanding sustained platelet threshold, but only a subset achieved it and individual priorities differ across bleeding, rescue use, fatigue, convenience and cost. Real-world use could concentrate in selected refractory patients rather than broadly displace existing options. An oral immune-modulating mechanism may still be attractive where patients cycle through or cannot tolerate current therapies.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: NMPA approval; adult persistent or chronic primary ITP; inadequate response or intolerance to prior treatment; Genzyme applicant; Class 1 innovative-drug designation. Independent corroboration: randomized, peer-reviewed Phase 3 results and the US prescribing record. Missing facts: Chinese label detail, launch date, price, reimbursement and local exposure and subgroup analyses. Upgrade evidence would be rapid reimbursement, broad hospital access and durable real-world platelet and bleeding outcomes.<\/p>\n

Company and Product Background<\/h4>\n

Sanofi acquired rilzabrutinib through its 2020 acquisition of Principia Biopharma. Genzyme Corporation is the regulatory applicant. In the United States, the medicine is branded Wayrilz and is indicated for adults with persistent or chronic ITP after insufficient response to prior therapy. China uses the brand name Sailizhi according to the approval disclosure.<\/p>\n

ITP is an autoimmune blood disorder in which antibody- and cellular-immune mechanisms accelerate platelet destruction and impair platelet production, increasing bleeding risk and affecting quality of life. BTK is expressed in B cells and innate immune cells. Rilzabrutinib forms a reversible covalent interaction with BTK, aiming for sustained target engagement while allowing the bond to reverse rather than permanently inactivating the kinase.<\/p>\n

InSilens Take<\/h4>\n

The China approval is a high-importance hematology signal because it converts an already validated program into a new national market and expands the therapeutic menu for previously treated ITP. Its direction is positive at the regulatory level, not automatically at the commercial level. The governing unknowns are local launch execution, reimbursement, label wording and whether a reversible covalent BTK inhibitor delivers durable clinical value outside a selected trial population.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — China approval materially expands the regulatory footprint of the first approved BTK-inhibitor approach in ITP and addresses a priority rare-blood-disease market<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — approval is a favorable regulatory event; commercial uptake and comparative clinical value remain unproven<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — the indication and applicant were reported from the NMPA source and corroborated by established global regulatory and peer-reviewed records<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-high — the regulatory importance is clear, while access, reimbursement and treatment-sequencing consequences remain uncertain<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

China’s National Medical Products Administration approved Genzyme Corporation’s rilzabrutinib tablets, branded Sailizhi in China, for adults with persistent or chronic primary immune thrombocytopenia who respond inadequately to or cannot tolerate corticosteroids, immunoglobulin or other…<\/p>\n","protected":false},"author":1,"featured_media":3074,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[274,728,727],"class_list":["post-3071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-btk-inhibitor","tag-immune-thrombocytopenia","tag-rilzabrutinib"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3071"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3071\/revisions"}],"predecessor-version":[{"id":3089,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3071\/revisions\/3089"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3074"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}